Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global regional and national burden and trends of early-onset Parkinson's disease from 1990 to 2021.

NPJ Parkinson's disease·2026
Same author

[Characteristics of the Pathogenic Bacteria Isolated from the Lower Respiratory Tract of the Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease].

Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition·2026
Same author

Understanding the immune microenvironment of ovarian cancer.

Frontiers in oncology·2026
Same author

Sequence Types of <i>Cryptococcus neoformans</i> and Their Associations with Clinical Characteristics and Outcomes of AIDS Patients with Cryptococcal Meningitis in Southern China.

Pathogens (Basel, Switzerland)·2026
Same author

Identification of a novel major QTL and F-box candidate genes controlling seed dormancy in common wheat.

TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik·2026
Same author

Venetoclax plus Idarubicin and cytarabine as frontline induction for newly diagnosed acute myeloid leukemia in young, fit adults: a real-world study.

Annals of hematology·2026
Same journal

Alectinib shows promise for the treatment of refractory ALK-positive large B-cell lymphoma: a case report.

Frontiers in oncology·2026
Same journal

Case Report: Neoadjuvant chemoimmunotherapy achieving pathological complete response in two cases of stage III EGFR-mutant NSCLC with high PD-L1 expression.

Frontiers in oncology·2026
Same journal

Expert consensus from the Chinese medical association on pharmaceutical management of combined cardio-oncology physician-pharmacist clinics.

Frontiers in oncology·2026
Same journal

Comparative efficacy and safety of etoposide plus PEG-rhG-CSF versus etoposide plus G-CSF for haematopoietic stem cell mobilisation in patients with multiple myeloma and lymphoma.

Frontiers in oncology·2026
Same journal

The aMAP score improves discrimination of prognostic models in hepatocellular carcinoma after radiofrequency ablation.

Frontiers in oncology·2026
Same journal

Cuproptosis and prostate cancer: from molecular mechanisms and microenvironment remodeling to precision therapy.

Frontiers in oncology·2026
See all related articles

Related Experiment Video

Updated: May 15, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

13.9K

A potential prognostic marker for hematologic neoplasms: CD58.

Jiajia Cao1, Yurong Zhang1, Ningning Yue1

  • 1Department of Hematology, The Second Hospital of Lanzhou University, Lanzhou, China.

Frontiers in Oncology
|May 14, 2025
PubMed
Summary
This summary is machine-generated.

CD58 protein is crucial for T/NK cell activation. Aberrant CD58 expression impacts hematologic tumor prognosis and CAR cell therapy resistance, highlighting its future therapeutic potential.

Keywords:
CD2 antigensCD58 antigensbiomarkerhematologic neoplasmsimmunological synapses

More Related Videos

Colony Forming Cell CFC Assay for Human Hematopoietic Cells
11:30

Colony Forming Cell CFC Assay for Human Hematopoietic Cells

Published on: December 18, 2010

35.5K
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

11.5K

Related Experiment Videos

Last Updated: May 15, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

13.9K
Colony Forming Cell CFC Assay for Human Hematopoietic Cells
11:30

Colony Forming Cell CFC Assay for Human Hematopoietic Cells

Published on: December 18, 2010

35.5K
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

11.5K

Area of Science:

  • Immunology
  • Oncology
  • Cell Biology

Background:

  • CD58 is a glycoprotein receptor found on histiocytes that binds to CD2, playing a role in immunological synapse formation and T/NK cell activation.
  • Altered CD58 expression is linked to poorer outcomes in hematological malignancies like leukemia and lymphoma.
  • Aberrant CD58 expression is implicated in drug resistance and immune rejection within CAR cell therapy.

Purpose of the Study:

  • To explore the multifaceted roles of CD58 in immune cells.
  • To elucidate the impact of CD58 on hematological oncology.
  • To discuss the implications of CD58 in immunotherapies, specifically CAR cell therapy.

Main Methods:

  • Literature review and synthesis of existing research on CD58.
  • Analysis of CD58's functional mechanisms in immune cell interactions.
  • Examination of clinical data and studies relating CD58 expression to hematological tumor prognosis and CAR cell therapy outcomes.

Main Results:

  • CD58's critical function in immune cell activation and immunological synapse formation is confirmed.
  • Significant correlations between aberrant CD58 expression and adverse prognostic factors in leukemia and lymphoma are evident.
  • CD58's aberrant expression presents a challenge in CAR cell therapy, contributing to treatment resistance and immune rejection.

Conclusions:

  • CD58 is a key player in immune regulation with significant implications for hematological oncology.
  • Targeting or modulating CD58 expression may offer novel therapeutic strategies for hematological malignancies.
  • Understanding CD58's role is vital for advancing CAR cell therapy and overcoming resistance mechanisms.